Interpace Biosciences, Inc. (IDXG) stock
IDXGOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/30
$5.00−0.15 (-2.91%)
Close on Oct 19, 2026Market cap $138.57MP/E 5.6Yield –
Interpace Biosciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Interpace Biosciences's operating income for the twelve months ending Jun 30, 2026 was $4.17M, down 27.2% year over year. For fiscal 2025 it was $4.08M, down 49.6% from the year before. The highest annual figure on record is $8.11M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.08M | -49.6% |
| FY2024 | Dec 31, 2024 | $8.11M | +105.0% |
| FY2023 | Dec 31, 2023 | $3.96M | – |
| FY2022 | Dec 31, 2022 | -$3.62M | – |
| FY2021 | Dec 31, 2021 | -$6.34M | – |
| FY2020 | Dec 31, 2020 | -$26.07M | – |
| FY2019 | Dec 31, 2019 | -$26.44M | – |
| FY2018 | Dec 31, 2018 | -$12.63M | – |
| FY2017 | Dec 31, 2017 | -$6.29M | – |
| FY2016 | Dec 31, 2016 | -$6.44M | – |
| FY2015 | Dec 31, 2015 | -$40.41M | – |
| FY2014 | Dec 31, 2014 | -$17.83M | – |
| FY2013 | Dec 31, 2013 | -$1.44M | – |
| FY2012 | Dec 31, 2012 | -$25.23M | – |
| FY2011 | Dec 31, 2011 | -$4.70M | – |
| FY2010 | Dec 31, 2010 | -$6.90M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $321.00K | – |
| Q1 FY2026 | Mar 31, 2026 | $1.12M | -38.6% |
| Q4 FY2025 | Dec 31, 2025 | $1.58M | -23.5% |
| Q3 FY2025 | Sep 30, 2025 | $1.15M | -50.2% |
| Q2 FY2025 | Jun 30, 2025 | -$468.00K | -117.8% |
| Q1 FY2025 | Mar 31, 2025 | $1.83M | +64.2% |
| Q4 FY2024 | Dec 31, 2024 | $2.06M | +38.3% |
| Q3 FY2024 | Sep 30, 2024 | $2.30M | +458.5% |
| Q2 FY2024 | Jun 30, 2024 | $2.63M | +116.4% |
| Q1 FY2024 | Mar 31, 2024 | $1.11M | +32.9% |
| Q4 FY2023 | Dec 31, 2023 | $1.49M | +2659.3% |
| Q3 FY2023 | Sep 30, 2023 | $412.00K | – |
| Q2 FY2023 | Jun 30, 2023 | $1.22M | – |
| Q1 FY2023 | Mar 31, 2023 | $838.00K | – |
| Q4 FY2022 | Dec 31, 2022 | $54.00K | – |
| Q3 FY2022 | Sep 30, 2022 | -$780.00K | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.91M | – |
| Q1 FY2022 | Mar 31, 2022 | -$977.00K | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.35M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.83M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.91M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.82M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.94M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.01M | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.77M | – |
| Q1 FY2020 | Mar 31, 2020 | -$6.35M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.77M | – |
| Q3 FY2019 | Sep 30, 2019 | -$7.13M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.35M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.18M | – |
| Q4 FY2018 | Dec 31, 2018 | -$5.02M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.47M | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.90M | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.25M | -187.8% |
| Q4 FY2017 | Dec 31, 2017 | -$3.30M | -148.9% |
| Q3 FY2017 | Sep 30, 2017 | -$3.10M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.60M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.70M | – |
| Q4 FY2016 | Dec 31, 2016 | $6.74M | – |
| Q3 FY2016 | Sep 30, 2016 | -$6.49M | – |
See a number that looks wrong?